CRP and CD14 polymorphisms correlate with coronary plaque volume in patients with coronary artery disease - IVUS substudy of the ENCORE trials

Atherosclerosis

Volumn 220, Issue 1, 2012, Pages 172-176

  Hermann, Matthias ^a   Fischer, Dieter ^b   Hoffmann, Michael M ^c   Gasser, Theo ^d   Quitzau, Kurt ^a   Meinertz, Thomas ^e   Münzel, Thomas ^f   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Coronary disease; Genetics; Inflammation; Plaque

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; CERIVASTATIN; NIFEDIPINE;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG DOSE INCREASE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; INTRAVASCULAR ULTRASOUND; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTIGENS, CD14; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84155162478     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.10.019     Document Type: Article

References (29)

1. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995, 92:657-671.
2. Goyert S.M., Ferrero E., Rettig W.J., Yenamandra A.K., Obata F., Le Beau M.M. The CD14 monocyte differentiation antigen maps to a region encoding growth factors and receptors. Science 1988, 239:497-500.
3. Ulevitch R.J., Tobias P.S. Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol 1999, 11:19-22.
4. Beekhuizen H., Blokland I., Corsel-van Tilburg A.J., Koning F., van Furth R. CD14 contributes to the adherence of human monocytes to cytokine-stimulated endothelial cells. J Immunol 1991, 147:3761-3767.
5. Arroyo-Espliguero R., El-Sharnouby K., Vazquez-Rey E., Kalidas K., Jeffery S., Kaski J.C. CD14 C(-260)T promoter polymorphism and prevalence of acute coronary syndromes. Int J Cardiol 2005, 98:307-312.
6. Unkelbach K., Gardemann A., Kostrzewa M., Philipp M., Tillmanns H., Haberbosch W. A new promoter polymorphism in the gene of lipopolysaccharide receptor CD14 is associated with expired myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol 1999, 19:932-938.
7. Shimada K., Watanabe Y., Mokuno H., Iwama Y., Daida H., Yamaguchi H. Common polymorphism in the promoter of the CD14 monocyte receptor gene is associated with acute myocardial infarction in Japanese men. Am J Cardiol 2000, 86(682-684):A688.
8. Hubacek J.A., Rothe G., Pit'ha J., et al. C(-260)→T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999, 99:3218-3220.
9. Giacconi R., Caruso C., Lio D., et al. CD14 C (-260)T polymorphism, atherosclerosis, elderly: role of cytokines and metallothioneins. Int J Cardiol 2007, 120:45-51.
10. Porsch-Ozcurumez M., Hucke J., Westphal S., Hubacek J.A., Schmitz G., Luley C. Post hoc analysis on the CD14 C(-260)T promoter polymorphism and coronary heart disease. Physiol Res 2007, 56:727-733.
11. Heesen M., Blomeke B., Schluter B., Heussen N., Rossaint R., Kunz D. Lack of association between the -260 C→T promoter polymorphism of the endotoxin receptor CD14 gene and the CD14 density of unstimulated human monocytes and soluble CD14 plasma levels. Intensive Care Med 2001, 27:1770-1775.
12. Zee R.Y., Lindpaintner K., Struk B., Hennekens C.H., Ridker P.M. A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction. Atherosclerosis 2001, 154:699-702.
13. Nauck M., Winkelmann B.R., Hoffmann M.M., Bohm B.O., Wieland H., Marz W. C(-260)T polymorphism in the promoter of the CD14 gene is not associated with coronary artery disease and myocardial infarction in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Am J Cardiol 2002, 90:1249-1252.
14. Eklund C., Kivimaki M., Islam M.S., et al. C-reactive protein genetics is associated with carotid artery compliance in men in the Cardiovascular Risk in Young Finns Study. Atherosclerosis 2008, 196:841-848.
15. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
16. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
17. Brull D.J., Serrano N., Zito F., et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003, 23:2063-2069.
18. D'Aiuto F., Casas J.P., Shah T., Humphries S.E., Hingorani A.D., Tonetti M.S. C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis 2005, 179:413-417.
19. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (evaluation of nifedipine and cerivastatin on recovery of coronary endothelial function). Circulation 2003, 107:422-428.
20. Luscher T.F., Pieper M., Tendera M., et al. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J 2009.
21. Hermann M., Hellermann J.P., Quitzau K., et al. CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease - the ENCORE trials. Atherosclerosis 2009, 207:476-479.
22. Mintz G.S., Nissen S.E., Anderson W.D., et al. American College of Cardiology Clinical Expert Consensus Document on Standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001, 37:1478-1492.
23. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
24. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28.
25. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959-1965.
26. McMurray J.J., Kjekshus J., Gullestad L., et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009, 120:2188-2196.
27. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
28. Arenillas J.F., Massot A., Alvarez-Sabin J., et al. C-reactive protein gene C1444T polymorphism and risk of recurrent ischemic events in patients with symptomatic intracranial atherostenoses. Cerebrovasc Dis (Basel, Switzerland) 2009, 28:95-102.
29. Bernardo E., Angiolillo D.J., Ramirez C., et al. Influence of the CD14 C260T promoter polymorphism on C-reactive protein levels in patients with coronary artery disease. Am J Cardiol 2006, 98:1182-1184.